A Prospective Study Investigating the Relationship Between Minimal Residual Disease Detection, Monitoring Frequency, and Prognosis in Non-small Cell Lung Cancer Patients Eligible for Curative Treatment.
N/A
Adding immune checkpoint inhibitors or molecularly targeted drugs as adjuva...
Status
Not Yet Recruiting
Location
National Cancer Center Hospital
Start Date
2025-03-01
Trial ID
NCT06854939
Signatera Assessment in Early-Stage Endometrial Cancer
NA
The goal of this clinical trial is to assess if circulating tumor DNA can g...
Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial
PHASE2
This clinical trial studies whether measuring circulating tumor deoxyribonu...
Status
Recruiting
Location
Fred Hutch/University of Washington Cancer Consortium
A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)
PHASE2
The NSABP FC-13 study is being done to determine if using immunotherapies a...
A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.
NA
This is a multicenter, open-label, randomized (1:1) trial designed to evalu...